{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:42:02Z","timestamp":1777430522857,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Classically, clinical trials are based on the placebo\u2010control design. Our aim was to analyze the placebo effect in Huntington's disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Placebo data were obtained from an international, longitudinal, placebo\u2010controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One\u2010hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10% of the population met it.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16% (first visit) to 41% (last visit). Nondepressed patients with better functional status were most likely to be placebo\u2010responders over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function \u00a9 2011 Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.24062","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T09:31:28Z","timestamp":1323423088000},"page":"439-442","source":"Crossref","is-referenced-by-count":17,"title":["Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease"],"prefix":"10.1002","volume":"27","author":[{"given":"Esther","family":"Cubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"del Puerto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justo Garcia","family":"de Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Fern\u00e1ndez","family":"Arconada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Trejo","family":"Gabriel y Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the European Huntington's Disease Initiative Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"e_1_2_7_3_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1060937"},{"key":"e_1_2_7_3_3_2","first-page":"MS54","article-title":"Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries","volume":"11","author":"Fricchione G","year":"2005","journal-title":"Med Sci Monit"},{"key":"e_1_2_7_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.11.019"},{"key":"e_1_2_7_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00038-8"},{"key":"e_1_2_7_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21181"},{"key":"e_1_2_7_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_7_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21897"},{"key":"e_1_2_7_3_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.710"},{"key":"e_1_2_7_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10024"},{"key":"e_1_2_7_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"e_1_2_7_3_12_2","first-page":"217","volume-title":"CGI: Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_7_3_13_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Yoav B","year":"1995","journal-title":"J R Soc Series B Stat Methodol"},{"key":"e_1_2_7_3_14_2","unstructured":"R Foundation for Statistical Computing. The R Project for Statistical Computing. Vienna Austria: R Foundation for Statistical Computing; 2011. Available at:http:\/\/www.r\u2010project.org. Accessed November 20 2011."},{"key":"e_1_2_7_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22405"},{"key":"e_1_2_7_3_16_2","first-page":"430","article-title":"Trazodone in the treatment of neurotic depression","volume":"41","author":"Goldberg HL","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_3_17_2","first-page":"68","article-title":"Comparison of the therapeutic efficacy of amoxapine with that of imipramine","volume":"16","author":"Kiev A","year":"1979","journal-title":"Clin Trials J"},{"key":"e_1_2_7_3_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.138.1.20"},{"key":"e_1_2_7_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00966-5"},{"key":"e_1_2_7_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23574"},{"key":"e_1_2_7_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.9.1326"},{"key":"e_1_2_7_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01355.x"},{"key":"e_1_2_7_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130609"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.24062","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.24062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.24062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:35:33Z","timestamp":1760967333000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.24062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/mds.24062"],"URL":"https:\/\/doi.org\/10.1002\/mds.24062","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]}}}